Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.

Medicine & Life Sciences

• Sunitinib 100%
• Vascular Endothelial Growth Factor Receptor 93%
• vatalanib 90%
• Sorafenib 63%
• Lung Neoplasms 61%
• 3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide 59%
• cediranib 44%
• N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine 41%
• Axitinib 40%
• Bevacizumab 28%
• ErbB Receptors 24%
• Protein-Tyrosine Kinases 23%
• Vascular Endothelial Growth Factor A 22%
• Drug Therapy 15%
• Antibodies 14%
• Therapeutics 12%